Metrics as of 10/15/2026, 12:38 PM (Berlin time), refresh in progress.
MaxCyte Stock
MaxCyte, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Maher Masoud
- Employees
- 91
- Market cap
- $129 M
- IPO
- 29/07/2021
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein…
MaxCyte stock: price history
1D
+29.6%
1W
+20.2%
1M
+5.9%
6M
+47.9%
YTD
-19.4%
1Y
-24.2%
2Y
-67.7%
5Y
-88.7%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~52% stronger price swings than usual
Ask the agents about MaxCyte
Analyst assessment of MaxCyte
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
4
BUY
2
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 25/03/2026
MaxCyte stock metrics
P/E
-3.74
P/B
0.84
EV/EBITDA
-4.26
RETURN ON EQUITY
-5.6%
NET MARGIN
-122.0%
DEBT/EQUITY
0.11
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.8%
FLOAT SHARES
94,757,337
AVG. DAILY VOLUME (30D)
756,309
Insider transactions (SEC)
Al-Wakeel Yasir B.
BALTHROP PATRICK J
Brooke William W
Collins Cynthia
DOUGLAS RICHARD
Institutional holders
Comparable stocks
Frequently asked questions about MaxCyte stock
What does MaxCyte do?
MaxCyte, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Maher Masoud, the company employs around 91 people.
The IPO was on 29/07/2021; the stock trades on NASDAQ under the ticker MXCT.
What do analysts say about MaxCyte stock?
6 analysts rate the stock, the consensus is Buy (as of 25/03/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does MaxCyte report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 52% stronger than usual.
Does MaxCyte pay a dividend?
No, MaxCyte currently does not pay a dividend.
Which stocks are comparable to MaxCyte?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MaxCyte stock analyzed?
Clicking "Analyze stock" lets five strategies assess MaxCyte against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.